The double challenge of resistant hypertension and chronic kidney disease (Q38623743)

4 September 2017

The double challenge of resistant hypertension and chronic kidney disease (English)

1 reference

4 September 2017

1 reference

6

Adrian Covic

1 reference

4 September 2017

13

Raymond Vanholder

1 reference

4 September 2017

1

Patrick Rossignol

1 reference

4 September 2017

Alberto Ortiz

12

0 references

Andrzej Więcek

14

object named as

Andrzej Wiecek

1 reference

4 September 2017

16

Gérard Michel London

1 reference

4 September 2017

18

Denis Fouque

1 reference

4 September 2017

2

Ziad A Massy

1 reference

4 September 2017

10

Mehmet Kanbay

1 reference

4 September 2017

11

Francesca Mallamaci

1 reference

4 September 2017

Michel Azizi

3

1 reference

4 September 2017

George Bakris

4

1 reference

4 September 2017

Eberhard Ritz

5

1 reference

4 September 2017

David Goldsmith

7

1 reference

4 September 2017

Gunnar H Heine

8

1 reference

4 September 2017

Kitty J Jager

9

1 reference

4 September 2017

Carmine Zoccali

15

1 reference

4 September 2017

Bénédicte Stengel

17

1 reference

4 September 2017

ERA-EDTA EURECA-m working group

19

1 reference

4 September 2017

Red de Investigación Renal (REDINREN) network

20

1 reference

4 September 2017

Cardiovascular and Renal Clinical Trialists (F-CRIN INI-CRCT) network

21

1 reference

4 September 2017

language of work or name

English

0 references

publication date

1 October 2015

1 reference

4 September 2017

1 reference

4 September 2017

386

1 reference

4 September 2017

10003

1 reference

4 September 2017

1588-1598

1 reference

Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research

4 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Resistant hypertension--its identification and epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Prevalence of resistant hypertension in the United States, 2003-2008.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Epidemiology and prognostic significance of chronic kidney disease in the elderly--the Three-City prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Prevalence of apparent treatment-resistant hypertension among individuals with CKD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Prevalence and factors associated with resistant hypertension in a large health maintenance organization in Israel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Incidence and prognosis of resistant hypertension in hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Prognostic significance of a reduced glomerular filtration rate and interaction with microalbuminuria in resistant hypertension: a cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Plasma free metanephrine and normetanephrine levels are increased in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Drug-induced hypertension: an unappreciated cause of secondary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Resistant hypertension: an overview of evaluation and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

The prevalence, incidence, prognosis, and associated conditions of resistant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Resistant hypertension? Assessment of adherence by toxicological urine analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Adherence to antihypertensive agents and blood pressure control in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Drug adherence in chronic kidney diseases and dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Epidemiology of resistant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Cognitive disorders and dementia in CKD: the neglected kidney-brain axis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Prevalence of true therapeutic inertia in blood pressure control in an academic chronic kidney disease clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Suboptimal blood pressure control in chronic kidney disease stage 3: baseline data from a cohort study in primary care.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Arterial stiffness and pulse pressure in CKD and ESRD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Reduced baroreflex sensitivity is associated with increased vascular calcification and arterial stiffness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Determinants of baroreflex function in juvenile end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Arterial stiffness, cardiovagal baroreflex sensitivity and postural blood pressure changes in older adults: the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Relationship between sympathetic baroreflex sensitivity and arterial stiffness in elderly men and women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Salt and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Management of hypertension: summary of NICE guidance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Resistant hypertension revisited: a comparison of two university-based cohorts.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

A randomized trial of dietary sodium restriction in CKD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Spot urine tests in predicting 24-hour urine sodium excretion in Asian patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

A different view on sodium balance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Magnetic resonance-determined sodium removal from tissue stores in hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Loop diuretics: from the Na-K-2Cl transporter to clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in non-dialysis-dependent chronic kidney disease: an endorsement with

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Combined angiotensin inhibition for the treatment of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Efficacy and safety of combined vs. single renin-angiotensin-aldosterone system blockade in chronic kidney disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Effect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Aldosterone antagonists for preventing the progression of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

A controlled trial of renal denervation for resistant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Limited destruction of renal nerves after catheter-based renal denervation: results of a human case study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Renal denervation in moderate to severe CKD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Effects of baroreflex activation therapy on arterial stiffness and central hemodynamics in patients with resistant hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Impact of baroreflex activation therapy on renal function--a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Revascularization versus medical therapy for renal-artery stenosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Stenting and medical therapy for atherosclerotic renal-artery stenosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

Where now in the management of renal artery stenosis? Implications of the ASTRAL and CORAL trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900418-3

7 January 2021

10.1016/S0140-6736(15)00418-3

Identifiers

DOI

1 reference

release_6mtomqtur5ggfauereo2eqmqii

4 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6mtomqtur5ggfauereo2eqmqii

24 November 2022

mapped directly with Wikidata item

1 reference